Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02729298
Title First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Arizona Phoenix Arizona 85054 United States Details
HonorHealth Research Institute Scottsdale Arizona 85258 United States Details
University of Colorado Denver Denver Colorado 80045 United States Details
US Oncology - Rocky Mountain Cancer Centers, LLP (RMCC) Denver Colorado 80218 United States Details
Mayo Clinic Florida Jacksonville Florida 32224 United States Details
Miami Cancer Institute Miami Florida 33176 United States Details
University of Kansas Cancer Center Fairway Kansas 66205 United States Details
Mayo Clinic Rochester Rochester Minnesota 55905 United States Details
US Oncology - Willamette Valley Cancer Institute and Research Center Eugene Oregon 97401 United States Details
US Oncology - Texas Oncology Austin Austin Texas 78705 United States Details
University of Texas Southwestern Medical Center Dallas Texas 75390 United States Details
US Oncology - Texas Oncology - Fort Worth Fort Worth Texas 76104 United States Details
University of Texas Science Center at San Antonio (UTHSCSA) San Antonio Texas 78229 United States Details
US Oncology - Texas Oncology - Tyler Tyler Texas 75702 United States Details
US Oncology - Virginia Cancer Specialists (VCS) Fairfax Virginia 22031 United States Details
Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field